Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide dose-ranging phase 3 study in Cushing's disease
2006-004111-22Phase 3Terminated
- Sponsor
- Novartis
- Start
- Nov 2006
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pasireotide LAR in Corticotropin adenoma (ACTHoma) (2 arms), sponsored by Novartis. Primary endpoints: Biochemical response at month 6 in pasireotide 600 micrograms twice daily arm and Biochemical response at month 6 in pasireotide 900 micrograms twice daily arm. Started Nov 2006; status: terminated.
02
Drugs
pasireotide LAR
03
Conditions
Corticotropin adenoma (ACTHoma)
Beyond the preview
Go deeper on 2006-004111-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004111-22.